Press Releases

Press Releases
Date Title and Summary View
08/03/2017 FDA granted Breakthrough Therapy designation to the Company's drug candidate, GMI-1271, for treatment of adults with relapsed/refractory acute myeloid leukemia (AML) Company completed enrollment in the in Phase 2 portion of its Phase 1/2 trial of GMI-1271 for the treatment of AML ...
07/06/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Patent Office has issued an "intention to grant" letter for European Patent Application Number EP12813711.1, titled "E-Selectin Antagonist Compounds, Compositions, and Methods of Use." This patent is part ...
06/12/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) announced today the appointment of Patricia S. Andrews, chief executive officer and director of Boston Biomedical, Inc., to its Board of Directors. "It's an asset to our Board and GlycoMimetics as a whole to be able to le...
06/05/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies 2017 Global Healthcare Conference in New York City, on Wednesday, June 7, 2017, at 2:00 p.m. ET. To access the liv...
06/05/2017 Remission rates continue to be higher than historical controls and induction-related mortality continues to be lower than historical controls GMI-1271 continues to be well tolerated in combination with induction chemotherapy Only one case of severe (Grade...
05/31/2017 Clinical trial now fully enrolled with 91 patients: 25 in newly diagnosed arm and 66 in relapsed refractory arm Interim data to be presented at ASCO and EHA Meetings showing high remission rates with acceptable tolerability Patients with higher levels of novel bioma...
05/30/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,0...
05/25/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Commission, based on a favorable recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products, has granted orphan designation for the company's drug candidate GMI-1271 for ...
05/24/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public ...
05/22/2017 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, 6,000,000 shares of its common stock in an un...
1
... NextLast
Add to Briefcase = add release to Briefcase